ARTICLE | Clinical News
Semagacestat: Completed Phase III enrollment
December 21, 2009 8:00 AM UTC
Eli Lilly said that last quarter it completed enrollment of >1,500 patients in the double-blind, placebo-controlled Phase III IDENTITY trial comparing 100 or 140 mg oral semagacestat given once daily ...